Cullen Frost Bankers Inc. Takes Position in SAGE Therapeutics Inc (SAGE)

Cullen Frost Bankers Inc. bought a new position in SAGE Therapeutics Inc (NASDAQ:SAGE) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 600 shares of the biopharmaceutical company’s stock, valued at approximately $95,000.

Other institutional investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in SAGE Therapeutics by 6.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,106 shares of the biopharmaceutical company’s stock valued at $494,000 after acquiring an additional 175 shares in the last quarter. Quadrant Capital Group LLC lifted its position in SAGE Therapeutics by 4,871.4% during the first quarter. Quadrant Capital Group LLC now owns 348 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 341 shares during the period. Daiwa Securities Group Inc. lifted its position in SAGE Therapeutics by 1,284.2% during the first quarter. Daiwa Securities Group Inc. now owns 4,291 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 3,981 shares during the period. World Asset Management Inc purchased a new position in SAGE Therapeutics during the first quarter valued at $258,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in SAGE Therapeutics during the first quarter valued at $1,323,000.

In other news, CEO Jeffrey M. Jonas sold 84,661 shares of SAGE Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $174.83, for a total value of $14,801,282.63. Following the completion of the transaction, the chief executive officer now owns 97,851 shares of the company’s stock, valued at approximately $17,107,290.33. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Anne Marie Cook sold 15,000 shares of SAGE Therapeutics stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $166.14, for a total value of $2,492,100.00. Following the completion of the transaction, the senior vice president now directly owns 15,000 shares of the company’s stock, valued at approximately $2,492,100. The disclosure for this sale can be found here. In the last ninety days, insiders sold 319,284 shares of company stock valued at $54,221,641. 4.60% of the stock is owned by insiders.

Shares of SAGE traded down $0.21 during trading hours on Wednesday, hitting $174.15. The company had a trading volume of 664,964 shares, compared to its average volume of 585,537. The company has a debt-to-equity ratio of 0.03, a current ratio of 20.06 and a quick ratio of 20.06. The firm has a market cap of $8.91 billion, a PE ratio of -21.55 and a beta of 2.87. SAGE Therapeutics Inc has a 52-week low of $79.88 and a 52-week high of $178.16.

SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($3.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.17) by ($0.20). The firm had revenue of $0.47 million during the quarter. During the same period last year, the firm posted ($1.68) earnings per share. As a group, sell-side analysts anticipate that SAGE Therapeutics Inc will post -13.19 EPS for the current year.

Several brokerages have commented on SAGE. BidaskClub raised SAGE Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 5th. LADENBURG THALM/SH SH set a $220.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 2nd. Wedbush began coverage on SAGE Therapeutics in a research report on Wednesday, May 22nd. They set an “outperform” rating and a $207.00 price objective for the company. Raymond James reissued a “market perform” rating on shares of SAGE Therapeutics in a research report on Friday, April 26th. Finally, Oppenheimer set a $170.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research report on Sunday, May 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $202.15.

TRADEMARK VIOLATION WARNING: This news story was reported by Sundance Herald and is owned by of Sundance Herald. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sundanceherald.com/2019/05/29/600-shares-in-sage-therapeutics-inc-sage-acquired-by-cullen-frost-bankers-inc.html.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Recommended Story: How to Use a Moving Average for Trading 

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply